Therapy-related acute promyelocytic leukemia (t-APL) has been reported as a late complication of exposure to radiotherapy and/or chemotherapeutic agents targeting DNA topoisomerase II. We have analyzed in t-APL novel gene mutations recently associated with myeloid disorders. Unlike previous reports in acute myeloid leukemia (AML), our results showed neither IDHs nor TET2 mutations in t-APL. However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL.
Ottone, T., Cicconi, L., Hasan, S., Lavorgna, S., Divona, M., Voso, M. T., Montefusco, E., Melillo, L., Barragán, E., Platzbecker, U., Giannì, L., Hubmann, M., Pagoni, M., Amadori, S., Lo Coco, F., Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia, <<LEUKEMIA RESEARCH>>, 2012; 36 (4): 474-478. [doi:10.1016/j.leukres.2011.10.015] [http://hdl.handle.net/10807/2627]
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia
Voso, Maria Teresa;
2012
Abstract
Therapy-related acute promyelocytic leukemia (t-APL) has been reported as a late complication of exposure to radiotherapy and/or chemotherapeutic agents targeting DNA topoisomerase II. We have analyzed in t-APL novel gene mutations recently associated with myeloid disorders. Unlike previous reports in acute myeloid leukemia (AML), our results showed neither IDHs nor TET2 mutations in t-APL. However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
